Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVX 420

Next Previous
Drug Profile

AVX 420

Alternative Names: AVX-420; FOL-026

Latest Information Update: 18 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Coegin Pharma
  • Class Antifibrotics; Antineoplastics; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Kidney disorders; Leukaemia

Most Recent Events

  • 18 Dec 2024 Coegin Pharma plans a phase I trial for Leukaemia in 2025 (Coegin Pharma pipeline, December 2024)
  • 12 Jan 2022 AVX 420 is available for licensing as of 12 Jan 2022. https://coeginpharma.com/en/investor-relations/why-to-invest/
  • 12 Jan 2022 Coegin Pharma has patent protection for AVX 420 in Australia (Coegin Pharma website, January 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top